RELMADA THERAPEUTICS CFO Shenouda Maged bought 200,000 shares at $4.20 to $4.25 across two transactions. His post-transaction holding was 1,000,000 shares, making the purchase 20% of that disclosed position for investors assessing insider ownership.
Key Highlights
- Both transactions carried SEC transaction code P, indicating open-market purchases.
- Shenouda Maged bought 200,000 RELMADA THERAPEUTICS shares across two transactions.
- Following the transactions, Maged reported ownership of 1,000,000 shares.
His reported ownership following the purchases stood at 1,000,000 shares. Both entries used transaction code P. The purchases were attributed to Maged in his role as RELMADA THERAPEUTICS (NASDAQ: RLMD)’ chief financial officer. The reported 1,000,000-share position is the holding stated after both transactions.
Two Purchases Span September 9 and 10
The filing reported two separate transactions between September 9 and September 10. Each transaction used the same P classification. Transaction code P denotes an open-market or private purchase.
FAQs
Q: What was the impact of the purchase on Maged’s RLMD holding?
A: Following the two purchases, Maged’s reported ownership reached 1,000,000 RELMADA THERAPEUTICS shares. The filing identifies him as the company’s chief financial officer.
Q: When did the RELMADA THERAPEUTICS share purchases occur?
A: The two purchases occurred between September 9 and September 10, 2026. The filing lists both transactions under SEC transaction code P.
Q: What price range was reported for the share purchases?
A: The filing reported purchase prices ranging from $4.20 to $4.25 per share across the two transactions. It reported 200,000 shares acquired in total.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.